Mark J. Federspiel

Universität Innsbruck — Austria

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index5.8kcitations152works21.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(108), Animal Virus Infections Studies(36), Virology and Viral Diseases(31), Herpesvirus Infections and Treatments(27), Biomedical and Engineering Education(24)

Publications152 total

Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives
Journal of Medicinal Chemistry·2024· 4 citedOpen Access
P090 Ten year results of a phase i trial of oncolytic adenovirus-mediated sodium Iodide Symporter (nis) gene delivery in locally recurrent prostate cancer following primary radiotherapy
European Urology Open Science·2024Open Access
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
Nature Communications·2024· 59 citedOpen Access
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
Frontiers in Immunology·2023· 28 citedOpen Access
Supplemental Figure 3 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Figure 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplementary Figure Legends from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplementary Figure Legends from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Table 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Figure 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Figure 3 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Data from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Data from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplementary Table 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplementary Table 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Figure 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Table 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Supplemental Figure 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023Open Access
Data from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Table 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Stephen J. Russell(27), Evanthia Galanis(11), Kah-Whye Peng(10), Rae Myers(9), Suzanne Greiner(8), Ianko Iankov(6), Ileana Aderca(5), Angela Dispenzieri(5), Stephen H. Hughes(5), Glen N. Barber(5), K-W Peng(4), Guy E. Griesmann(4), Cory Allen(4), Mary Harvey(4), Diane Soeffker(4), Deborah C. Melder(4), Shruthi Naik(4), Sean C. Dowdy(3), David Dingli(3), Michael K. O’Connor(3)